Detalhe da pesquisa
1.
Efficacy of NVX-CoV2373 Covid-19 Vaccine against the B.1.351 Variant.
N Engl J Med
; 384(20): 1899-1909, 2021 05 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-33951374
2.
Efficacy of the ChAdOx1 nCoV-19 Covid-19 Vaccine against the B.1.351 Variant.
N Engl J Med
; 384(20): 1885-1898, 2021 05 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-33725432
3.
Severe Acute Respiratory Syndrome Coronavirus 2 Infection Among Healthcare Workers in South Africa: A Longitudinal Cohort Study.
Clin Infect Dis
; 73(10): 1896-1900, 2021 11 16.
Artigo
em Inglês
| MEDLINE | ID: mdl-33949670
4.
Immunogenicity and Safety of an Early Measles Vaccination Schedule at 6 and 12 Months of Age in Human Immunodeficiency Virus (HIV)-Unexposed and HIV-Exposed, Uninfected South African Children.
J Infect Dis
; 220(9): 1529-1538, 2019 09 26.
Artigo
em Inglês
| MEDLINE | ID: mdl-31282539
5.
Durability of ChAdOx1 nCoV-19 (AZD1222) vaccine and hybrid humoral immunity against variants including omicron BA.1 and BA.4 6 months after vaccination (COV005): a post-hoc analysis of a randomised, phase 1b-2a trial.
Lancet Infect Dis
; 23(3): 295-306, 2023 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-36273491
6.
Efficacy of primary series AZD1222 (ChAdOx1 nCoV-19) vaccination against SARS-CoV-2 variants of concern: Final analysis of a randomized, placebo-controlled, phase 1b/2 study in South African adults (COV005).
Vaccine
; 41(23): 3486-3492, 2023 05 26.
Artigo
em Inglês
| MEDLINE | ID: mdl-37149443
7.
Safety and immunogenicity of VPM1002 versus BCG in South African newborn babies: a randomised, phase 2 non-inferiority double-blind controlled trial.
Lancet Infect Dis
; 22(10): 1472-1483, 2022 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-35772447
8.
Immunogenicity and safety of a SARS-CoV-2 recombinant spike protein nanoparticle vaccine in people living with and without HIV-1 infection: a randomised, controlled, phase 2A/2B trial.
Lancet HIV
; 9(5): e309-e322, 2022 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-35489376
9.
Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 in people living with and without HIV in South Africa: an interim analysis of a randomised, double-blind, placebo-controlled, phase 1B/2A trial.
Lancet HIV
; 8(9): e568-e580, 2021 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-34416193
10.
Short-term immunogenicity and safety of hepatitis-A and varicella vaccines in HIV-exposed uninfected and HIV-unexposed South African children.
Vaccine
; 38(22): 3862-3868, 2020 05 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-32307279
11.
Immunogenicity of a single-dose compared with a two-dose primary series followed by a booster dose of ten-valent or 13-valent pneumococcal conjugate vaccine in South African children: an open-label, randomised, non-inferiority trial.
Lancet Infect Dis
; 20(12): 1426-1436, 2020 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-32857992